Oncology

News

David Campbell, founder, president and CEO of Janux

Janux plans $200m offer on back of prostate cancer readout

Buoyed by data from a trial of its T-cell engager (TCE) therapy in prostate cancer that almost tripled its share price, Janux Therapeutics has moved quickly to file a stoc

Oncology

Why is pharma going gaga for radiopharmaceuticals?

The pharma industry is always on the lookout for new therapeutic angles that might prove to be a competitive advantage.

News

Study rings warning bell over cancer therapy access in UK

Studies have suggested that cancer survival rates in the UK are lagging behind other countries by around 10 to 15 years because of lower rates of chemotherapy and radiothe

News

Regeneron set for August FDA decision on BCMA bispecific

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its lin

News

US, EU regulators start swift reviews of Servier glioma drug

The US FDA and EMA in the EU have started accelerated reviews of Servier’s vorasidenib for IDH-mutated low-grade glioma, which is vying to become the first targeted therapy for this a

News

AZ, Daiichi eye December verdict for TROP2 ADC

The FDA has started a review of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan as a therapy for lung cancer, the second drug in their antibody-drug conjugate (ADC

Janux plans $200m offer on back of prostate cancer readout

Why is pharma going gaga for radiopharmaceuticals?

Study rings warning bell over cancer therapy access in UK

Regeneron set for August FDA decision on BCMA bispecific

US, EU regulators start swift reviews of Servier glioma drug

AZ, Daiichi eye December verdict for TROP2 ADC

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks